Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Why Isis Pharmaceuticals Shares Popped

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of development stage biotechnology company Isis Pharmaceuticals (NASDAQ: IONS  )   jumped as much as 17% following the approval of Kynamro by the Food and Drug Administration.

So what: Kynamro, which was developed with Sanofi (NYSE: SNY  ) , is designed to treat homozygous familial hypercholesterolemia, or HoFH, a disease that makes it difficult to remove bad-LDL cholesterol from the body and can lead to cardiovascular disease. It shouldn't come as a surprise, though, that the drug was approved with a warning label that it can cause liver toxicity -- this was a repeated concern raised throughout its trials and by the FDA panel. Sanofi is expected to begin marketing the drug immediately at a price of between $125,000 and $200,000, according to BMO Capital Markets analyst Jim Birchenough.

Now what: Now we get to watch what unfolds when a rare disease suddenly gets two newly approved competing drugs all within a matter of weeks. Aegerion Pharmaceuticals' (NASDAQ: AEGR  ) Juxtapid was actually approved earlier than its PDUFA date by the FDA, albeit with the same liver toxicity warning. Isis will be relying on Sanofi's marketing expertise to unlike Kynamro's full potential which some analysts have pegged around $400 million in peak sales. Isis itself will get somewhere around 30% to 50% of the profits, depending on total sales of the drug. Aegerion, on the other hand, only partnered its drug, Juxtapid, with Catalent three weeks ago. Nothing against Catalent, but I'm giving Isis the upper hand with Sanofi in its corner. It should, nonetheless, be an interesting battle to watch!

Craving more input? Start by adding Isis Pharmaceuticals to your free and personalized watchlist so you can keep up on the latest news with the company.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2225092, ~/Articles/ArticleHandler.aspx, 10/1/2016 5:08:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,308.15 164.70 0.91%
S&P 500 2,168.27 17.14 0.80%
NASD 5,312.00 42.85 0.81%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/30/2016 4:00 PM
IONS $36.64 Up +1.07 +3.01%
Ionis Pharmaceutic… CAPS Rating: *****
SNY $38.19 Up +0.36 +0.95%
Sanofi CAPS Rating: *****
AEGR $2.97 Down -0.09 -2.94%
Aegerion Pharmaceu… CAPS Rating: **